Clinical and Biochemical Assessment of Maintenance Treatment in Chronic Recurrent Seborrheic Dermatitis: Randomized Controlled Study

Dermatology and Therapy - Tập 4 - Trang 43-59 - 2014
Virginie Turlier1, Cécile Viode2, Elisabeth Durbise3, Adeline Bacquey4, Ophélie LeJeune2, Rui Oliveira Soares5, Christophe Lauze6, Cécile Villeneuve2, Amandine Rouquier1, Christiane Casas2, Daniel Redoules7, Valérie Mengeaud1, Anne-Marie Schmitt8
1Service Exploration Clinique, Hôtel Dieu, Toulouse, France
2Service de Biologie Clinique, Hôtel Dieu, Toulouse, France
3Cahors, France
4Service Systemes et Methodes, Hôtel Dieu, Toulouse, France
5Hospital Cuf Descobertas-Parque das Nações, Lisbon, Portugal
6Pierre Fabre Biométrie, Labège Innopole, France
7Service Pharmacologie Clinique, Hôtel Dieu, Toulouse, France
8Centre de Recherche sur la Peau, Hôtel Dieu, Toulouse, France

Tóm tắt

Few studies have investigated the long-term effects of a maintenance regimen in the prevention of relapses in scalp seborrheic dermatitis (SD), in particular following biomarker changes. A new shampoo containing beta-glycyrrhetinic acid (18βGA) in addition to cyclopiroxolamine (CPO) and zinc pyrithione (ZP) was tested in 67 subjects suffering from SD with moderate to severe erythema and itching in a biphasic study. After a first common intensive treatment phase (investigational product thrice a week × 2 weeks), subjects randomly received the investigational product once a week × 8 weeks (maintenance) or a neutral shampoo (discontinuation) in a comparative, parallel group maintenance phase. Efficacy was assessed clinically (overall clinical dandruff score, erythema, overall efficacy, self-evaluation), biochemically and microbiologically by quantitative polymerase chain reaction (qPCR), high performance liquid chromatography (HPLC) or enzyme-linked immunoabsorbent assay (ELISA) analysis of scale samples (Malassezia species (restricta and globosa), cohesion proteins (plakoglobins), inflammation (Interleukin (IL)-8, IL-1RA/IL-1α) and pruritus (histamine, cathepsin S) markers). During the intensive treatment phase, SD improved significantly (p < 0.0001) with a decrease in clinical signs as well as Malassezia species, cohesion proteins, inflammation and pruritus markers. During the maintenance phase, the improvement persisted in the ‘maintenance’ group only, with a significant intergroup difference. A consistently positive relationship was found between dandruff, itching, erythema and Malassezia populations, histamine levels and IL-1RA/IL-1α ratio. The effectiveness of this maintenance regimen was objectively demonstrated at the clinical, biochemical and microbiological level. Correlations between clinical signs and biomarkers could provide clues to explain the resolution of SD and confirm the interest of biomarkers for SD treatment assessment.

Tài liệu tham khảo

Johnson M-LT, Roberts J. Prevalence of dermatological diseases among persons 1–74 years of age: United States. Advance data Report No. 4. U.S. Department of Health, Education, and Welfare. 1977. http://www.cdc.gov/nchs/data/series/sr_11/sr11_212.pdf. Last Accessed 1 June 2013.

Foley P, Zuo Y, Plunkett A, Merlin K, Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003;139:318–22.

Breunig Jde A, De Almeida HL Jr, Duquia RP, Souza PR, Staub HL. Scalp seborrheic dermatitis: prevalence and associated factors in male adolescents. Int J Dermatol. 2012;51:46–9.

Schwartz JR, Messenger AG, Tosti A, et al. A comprehensive pathophysiology of dandruff and seborrheic dermatitis—towards a more precise definition of scalp health. Acta Derm Venereol. 2013;93:131–7.

Jang SJ, Lim SH, Ko JH, et al. The investigation on the distribution of Malassezia yeasts on the normal Korean skin by 26S rDNA PCR-RFLP. Ann Dermatol. 2009;21:18–26.

Sandström Falk M-H, Tengvall Linder M, Johansson C, et al. The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol. 2005;85:17–23.

Tajima M, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol. 2008;128:345–51.

Oh BH, Lee YW, Choe YB, Ahn KJ. Epidemiologic study of Malassezia yeasts in seborrheic dermatitis patients by the analysis of 26S rDNA PCR-RFLP. Ann Dermatol. 2010;22:149–55.

Zhang H, Ran Y, Xie Z, Zhang R. Identification of Malassezia species in patients with seborrheic dermatitis in China. Mycopathologia. 2013;175:83–9.

Kerr K, Darcy T, Henry J, et al. Epidermal changes associated with symptomatic resolution of dandruff: biomarkers of scalp health. Int J Dermatol. 2011;50:102–13.

Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat. 2002;13:51–60.

Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol. 1986;114:695–700.

Saple DG, Ravichandran G, Desai A. Evaluation of safety and efficacy of ketoconazole 2% and zinc pyrithione 1% shampoo in patients with moderate to severe dandruff—a postmarketing study. J Indian Med Assoc. 2000;98:810–1.

Lassus A, Nolting KS, Savopoulos C. Comparison of ciclopirox olamine 1% cream with ciclopirox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. Clin Ther. 1988;10:594–9.

Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36:788–92.

Van Cutsem J, Van Gerven F, Fransen J, Schrooten P, Janssen PA. The in vitro antifungal activity of ketoconazole, zinc pyrithione, and selenium sulfide against Pityrosporum and their efficacy as a shampoo in the treatment of experimental pityrosporosis in guinea pigs. J Am Acad Dermatol. 1990;22:993–8.

McGinley KJ, Leyden JJ. Antifungal activity of dermatological shampoos. Arch Dermatol Res. 1982;272:339–42.

Warner RR, Schwartz JR, Boissy Y, Dawson TL Jr. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol. 2001;45:897–903.

Mills KJ, Hu P, Henry J, Tamura M, Tiesman JP, Xu J. Dandruff/seborrhoeic dermatitis is characterized by an inflammatory genomic signature and possible immune dysfunction: transcriptional analysis of the condition and treatment effects of zinc pyrithione. Br J Dermatol. 2012;166:S33–40.

Roques C, Brousse S, Panizzutti C. In vitro antifungal efficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restricta reference strains. Mycopathologia. 2006;162:395–400.

Lorette G, Ermosilla V. Clinical efficacy of a new ciclopirox olamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment. Eur J Dermatol. 2006;16:558–64.

Ishida T, Mizushina Y, Yagi S, et al. Inhibitory effects of glycyrrhetinic acid on DNA polymerase and inflammatory activities. Evid Based Complement Alternat Med. 2012;2012:650514.

Wang CY, Kao TC, Lo WH, Yen GC. Glycyrrhizic acid and 18β-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-κB through PI3K p110δ and p110γ inhibitions. J Agric Food Chem. 2011;59:7726–33.

Kerr K, Schwartz JR, Filloon T, et al. Scalp stratum corneum histamine levels: novel sampling method reveals association with itch resolution in dandruff/seborrhoeic dermatitis treatment. Acta Derm Venereol. 2011;91:404–8.

Shin H, Kwon OS, Won CH, et al. Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: a comparative study. J Dermatol. 2009;36:131–7.

Weiss SC, Rowell R, Krochmal L. Impact of seasonality on conducting clinical studies in dermatology. Clin Dermatol. 2008;26:565–9.

Reddy VB, Shimada SG, Sikand P, Lamotte RH, Lerner EA. Cathepsin S elicits itch and signals via protease-activated receptors. J Invest Dermatol. 2010;130:1468–70.

Viode C, Lejeune O, Villeneuve C, et al. Evidence of cathepsin S, PAR2 and histamine interest in pruritus aspect of clinical dandruff/seborrheic dermatitis evaluation-poster n° 107. Acta Dermatol Venereol. 2013;93:624.

Perkins MA, Osterhues MA, Farage MA, Robinson MK. A noninvasive method to assess skin irritation and compromised skin conditions using simple tape adsorption of molecular markers of inflammation. Skin Res Technol. 2001;7:227–37.

Perkins M, Cardin C, Osterhues M, Robinson M. A non-invasive tape absorption method for recovery of inflammatory mediators to differentiate normal from compromised scalp conditions. Skin Res Technol. 2002;8:187–93.

US Department of Health and Human Services FDA. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. 2004; http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm. Last Accessed 1 June 2013.

Thông tin
Thông tin xuất bản

Dermatology and Therapy

Tập 4

43-59

Thông tin tác giả